BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China
· Delayed Price · Currency is CNY 49.37
-1.75 (-3.42%)
At close: Jun 5, 2025, 2:57 PM CST
SHA:688166 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Net Income | 138.06 | 189.17 | 202.47 | 239.62 | 243.95 | 169.88 | Upgrade
|
| Depreciation & Amortization | 109.94 | 109.94 | 78.06 | 50.47 | 41.5 | 30.2 | Upgrade
|
| Other Amortization | 10.66 | 10.66 | 10.54 | 11.09 | 10.83 | 9.04 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | -0.01 | -0.01 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 8.39 | 8.39 | 1.75 | 1.57 | 0.26 | 0.27 | Upgrade
|
| Loss (Gain) From Sale of Investments | 11.97 | 11.97 | 12.41 | -3 | -10.02 | -3.59 | Upgrade
|
| Provision & Write-off of Bad Debts | 11.57 | 11.57 | 0.9 | -2.23 | 10.11 | -0.81 | Upgrade
|
| Other Operating Activities | 30.1 | 20.46 | 37.19 | -1.08 | 8.27 | 21.75 | Upgrade
|
| Change in Accounts Receivable | -149.93 | -149.93 | -17.85 | 4.96 | -241.94 | -50.51 | Upgrade
|
| Change in Inventory | -35.55 | -35.55 | -85.77 | -94.94 | -6.25 | -75.71 | Upgrade
|
| Change in Accounts Payable | 84.4 | 84.4 | -23.61 | 130.2 | 116.92 | 47.33 | Upgrade
|
| Change in Other Net Operating Assets | 15.75 | 15.75 | -2.96 | -21.31 | 4.16 | 11.65 | Upgrade
|
| Operating Cash Flow | 204.09 | 245.56 | 194.77 | 311.26 | 176.08 | 155.43 | Upgrade
|
| Operating Cash Flow Growth | -35.85% | 26.08% | -37.43% | 76.78% | 13.28% | 153.42% | Upgrade
|
| Capital Expenditures | -360.14 | -257.2 | -403.76 | -726.73 | -909.66 | -355.27 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.31 | 0.3 | 0.48 | 0.38 | 0.05 | 0.01 | Upgrade
|
| Cash Acquisitions | - | - | - | 0.01 | -7.5 | - | Upgrade
|
| Investment in Securities | -214.6 | -228.61 | -64.24 | -153.38 | 8.64 | -218.46 | Upgrade
|
| Other Investing Activities | 45.37 | 45.37 | 31.26 | 18.24 | 18.64 | 31.79 | Upgrade
|
| Investing Cash Flow | -529.06 | -440.14 | -439.85 | -871.58 | -889.84 | -541.92 | Upgrade
|
| Long-Term Debt Issued | - | 823.08 | 678.23 | 1,646 | 882.2 | 234.89 | Upgrade
|
| Total Debt Issued | 876.48 | 823.08 | 678.23 | 1,646 | 882.2 | 234.89 | Upgrade
|
| Long-Term Debt Repaid | - | -804.81 | -569.61 | -474.12 | -210.88 | -15.06 | Upgrade
|
| Total Debt Repaid | -888.2 | -804.81 | -569.61 | -474.12 | -210.88 | -15.06 | Upgrade
|
| Net Debt Issued (Repaid) | -11.71 | 18.27 | 108.62 | 1,172 | 671.32 | 219.83 | Upgrade
|
| Issuance of Common Stock | - | - | - | 219.81 | - | - | Upgrade
|
| Repurchase of Common Stock | -10.01 | -10.01 | - | - | - | - | Upgrade
|
| Common Dividends Paid | -126.29 | -135.73 | -115.01 | -100.1 | -54.3 | -35.4 | Upgrade
|
| Other Financing Activities | 303.9 | 103 | 68 | 73 | 86.7 | 1.3 | Upgrade
|
| Financing Cash Flow | 155.89 | -24.47 | 61.61 | 1,365 | 703.72 | 185.73 | Upgrade
|
| Foreign Exchange Rate Adjustments | 4.43 | 2.12 | 2.78 | 14.15 | 3.72 | -13.03 | Upgrade
|
| Net Cash Flow | -164.65 | -216.94 | -180.69 | 818.52 | -6.32 | -213.79 | Upgrade
|
| Free Cash Flow | -156.05 | -11.64 | -209 | -415.47 | -733.59 | -199.84 | Upgrade
|
| Free Cash Flow Margin | -13.10% | -0.91% | -17.72% | -40.84% | -69.71% | -25.45% | Upgrade
|
| Free Cash Flow Per Share | -0.37 | -0.03 | -0.49 | -1.01 | -1.80 | -0.48 | Upgrade
|
| Cash Income Tax Paid | 21.31 | 25.46 | 29.42 | -17.03 | -7.18 | -10.16 | Upgrade
|
| Levered Free Cash Flow | -223.43 | -65.73 | -316.64 | -515.42 | -785.87 | -241.66 | Upgrade
|
| Unlevered Free Cash Flow | -190 | -32.96 | -288.87 | -500.6 | -779.81 | -240.38 | Upgrade
|
| Change in Net Working Capital | 22.75 | 28.72 | 103.85 | -19.96 | 78.19 | 38.79 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.